Vor Bio, a clinical-stage cell and genome engineering company, announced that it will participate in the following upcoming investor conferences.
CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
BTIG Biotechnology Conference 2022 (Hybrid)
Fireside Chat: A pre-recorded fireside chat will be available via the conference website starting August 8, 2022 at 9:00 AM ET.
2022 Wedbush PacGrow Healthcare Conference (Virtual)
Panel: A View to a Kill(er Cell) - Part 1
Panel date/time: Wednesday, August 10, 2022, 1:10pm ET
A live webcast and archived replay of the panel will be available on the investors section of www.vorbio.com.
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com
